Article
Clonal Evolution in Multiple Myeloma.
Clinical lymphoma, myeloma & leukemia - 1 Aug 2016
Fakhri Bita, Vij Ravi
Abstract excerpt
Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
